Alpha Teknova, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephen Gunstream
- Full Time Employees
- 173
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2290 Bert Drive Hollister CA United States of America 95023
- IPO Date
- Jun 25, 2021
- CIK
- 0001850902
- Website
- teknova.com
- Similar Companies
- Business
- Alpha Teknova, Inc. (Nasdaq: TKNO) manufactures and supplies critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company offers lab essentials, including chemical formulations such as pre-poured agar plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, buffers, molecular biology reagents for sample manipulation, resuspension and purification, additives including amino acids, vitamins, minerals, IPTG and trace metals, as well as water for injection (WFI) quality water; and clinical solutions encompassing custom GMP-grade products for protein therapies, gene therapies, mRNA vaccines and diagnostic kits, available in formats including bottles, single-use bags from 1L to 200L, and cryopreservation media. Alpha Teknova serves pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic firms, academic institutions and government research entities in the life sciences market, with operations centered in the United States and international distribution. Founded in 1996 by Genentech scientist Ted Davis in Half Moon Bay, California, the company maintains headquarters at 2451 Bert Drive, Hollister, California. Alpha Teknova reports 2024 revenue of $37.7 million, reflecting 3% year-over-year growth, and provides 2025 guidance of $39-42 million; in July 2024, major shareholder Telegraph Hill Partners purchased approximately $15 million in shares at $1.24 each through private placement, increasing its stake to over 25 million shares; recent product launches include Tryptic Soy Agar settle plates for environmental monitoring, PluriFreeze cryopreservation system via collaboration with Pluristyx for allogeneic cell therapies, RUO+ manufacturing grade and Express- Tek production services for rapid custom formulations, alongside expanded single-use bag offerings and custom quality control testing.
Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript
Teknova Reports First Quarter 2026 Financial Results
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
Alpha Teknova Q4 Earnings Call Highlights
Alpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call Transcript
Teknova Reports Fourth Quarter and Full Year 2025 Financial Results
Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Alpha Teknova (NASDAQ:TKNO) Shares Up 2.6% – Should You Buy?
Alpha Teknova (NASDAQ:TKNO) Shares Down 1.3% – Here’s What Happened
Alpha Teknova, Inc. (TKNO) Q3 2025 Earnings Call Transcript
Teknova Reports Third Quarter 2025 Financial Results
Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025
Alpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call Transcript
Teknova Reports Second Quarter 2025 Financial Results
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript
Teknova Reports First Quarter 2025 Financial Results
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies